JPMorgan Chase & Co. Grows Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

JPMorgan Chase & Co. increased its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 106.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 95,244 shares of the company’s stock after buying an additional 49,028 shares during the period. JPMorgan Chase & Co. owned about 0.11% of Atea Pharmaceuticals worth $319,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of AVIR. BML Capital Management LLC increased its stake in shares of Atea Pharmaceuticals by 4.3% during the 3rd quarter. BML Capital Management LLC now owns 6,650,000 shares of the company’s stock valued at $22,278,000 after acquiring an additional 274,379 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Atea Pharmaceuticals by 55.2% in the second quarter. Dimensional Fund Advisors LP now owns 594,360 shares of the company’s stock valued at $1,968,000 after purchasing an additional 211,428 shares during the period. Marshall Wace LLP acquired a new position in Atea Pharmaceuticals during the second quarter worth approximately $603,000. FMR LLC raised its stake in Atea Pharmaceuticals by 2.8% during the third quarter. FMR LLC now owns 6,618,297 shares of the company’s stock worth $22,171,000 after purchasing an additional 182,174 shares during the period. Finally, Barclays PLC boosted its holdings in shares of Atea Pharmaceuticals by 74.5% in the 3rd quarter. Barclays PLC now owns 177,077 shares of the company’s stock valued at $593,000 after purchasing an additional 75,624 shares during the last quarter. Hedge funds and other institutional investors own 86.67% of the company’s stock.

Insider Buying and Selling

In other Atea Pharmaceuticals news, Director Franklin M. Berger sold 359,606 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $2.85, for a total value of $1,024,877.10. Following the completion of the transaction, the director now owns 451,897 shares in the company, valued at $1,287,906.45. This represents a 44.31 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 17.80% of the stock is owned by corporate insiders.

Atea Pharmaceuticals Trading Down 0.3 %

AVIR stock opened at $2.99 on Friday. The company has a market cap of $252.54 million, a PE ratio of -1.44 and a beta of 0.20. The stock has a 50-day moving average price of $3.23 and a two-hundred day moving average price of $3.45. Atea Pharmaceuticals, Inc. has a 12-month low of $2.75 and a 12-month high of $4.60.

Atea Pharmaceuticals (NASDAQ:AVIR) last posted its earnings results on Thursday, November 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.13. During the same quarter last year, the company posted ($0.40) EPS. Equities analysts forecast that Atea Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.